In an age of pandemic, healthcare policy has an immediate and very dramatic impact on markets and people’s lives. We ensure your voice gets heard with the decision-makers that count for your business.
In law firm life, Max von Olenhusen represented just one side of a healthcare issue. But, he couldn’t help but see the opportunities for both sides in a dispute. He transitioned to public affairs to become an advocate for “win-win” solutions with the potential to improve health outcomes for Europe and the global community.
Over a decade with Novartis, Max became a trusted adviser to European policymakers in the search for common ground on tough issues ranging from pricing and reimbursement to intellectual property and safety of medical devices. Academia and patient groups pay close attention to his policy positions and journalists seek out his opinion on the latest happenings in the institutions.
Today as part of the Acumen team, Max is especially focused on advising clients on market access issues for pharmaceutical products, regulatory issues of orphan medicines, intellectual property and EU competition law. With his steady resolve and sharp analytical mind, Max leads clients through some of their most difficult decisions. During a crisis, he is the adviser you want on your side.
- Bar Exam, Court of Hamburg (2001)
- JD, University of Hamburg (1998)